RxDoctor Payments Data

Michele Murphy Cook, MD

Clinical Cardiac Electrophysiology · Coeur D Alene, IDNPI 1700048451

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Medtronic at 46.4% of the total.

$14,427in general payments, 2019–2025

Across 171 payments — averaging $84.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Boston Scientific$4K
  • Abbott$3K
  • Johnson & Johnson$449
  • Atricure, Inc.$238
  • Cardiva Medical, Inc.$56
  • plus $130 from 3 others
$44,822in research payments, 2019–2025

Across 23 payments — averaging $1948.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$24K
  • Boston Scientific$21K

What the payments were for

  • Travel & lodging$7,50152%
  • Food & beverage$6,92748%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)54$6,699
Boston Scientific47$3,621
Abbott45$3,233
Johnson & Johnson12$449
Atricure, Inc.4$238
Cardiva Medical, Inc.4$56
Insmed, Inc.1$53
AstraZeneca2$42
Amgen2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$394,968
Medicare patients
1,200
Services billed
5,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban682$778,873
XareltoRivaroxaban340$437,283
EntrestoSacubitril/Valsartan61$99,354
Metoprolol Succinate595$8,867
Flecainide Acetate87$5,807
Dabigatran EtexilateDabigatran Etexilate Mesylate24$3,989
SotalolSotalol Hcl127$2,492
Diltiazem 24hr Er (Cd)Diltiazem Hcl84$2,375
Mexiletine Hcl13$1,683
Potassium Chloride45$1,034
Diltiazem 24hr ErDiltiazem Hcl23$952
ClopidogrelClopidogrel Bisulfate116$891
Digoxin36$788
Dofetilide11$777
Torsemide39$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$449$437,283340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →